

British Association of Dermatologists
Response to NICE Final Appraisal Determination
On the Single Technology Appraisal (STA)
Vismodegib for treating basal cell carcinoma [ID1043]

British Association of Dermatologists
Therapy & Guidelines and Skin Cancer committee sub-committees

On behalf of the British Association of Dermatologists, thank you for the opportunity to comment on the Final Appraisal Determination.

The British Association of Dermatologists is very disappointed by the decision by NICE not to recommend Vismodegib for treating patients with metastatic basal cell carcinoma, or locally advanced basal cell carcinoma that is inappropriate for surgery or radiotherapy, as featured in the final appraisal determination document for this single technology appraisal.

This decision means that a group of people with basal cell carcinoma, especially vulnerable patients with complex disease and limited further options, or those who seek help late in the disease, will be denied a viable treatment option to treat their condition, where other treatment modalities might be unsuitable. Vismodegib is sometimes the only treatment that can make a significant difference to the quality of life of this cohort of patients.

We will not be putting forward an official appeal but will follow development in this area with great interest.

Dr Nick Levell
BAD President

Dr Pamela McHenry
Chair, Therapy & Guidelines sub-committee

Dr Kurt Ayerst
Chair, Skin Cancer sub-committee